In order to corroborate the high inter- and intra-case variability of tau tracer binding, as observed with fluorescent imaging, we carried out quantitative phosphorimaging with [18F]THK-5117 in disease groups that had shown fluorescent tracer binding, i.e. Alzheimer’s disease and FTDP-17, as well as control cases (Fig. 7 and Additional file 1: Figure S6). Here, MAPT is linked to Alzheimer disease.